No Effect of the Altered Peptide Ligand NBI-6024 on β-Cell Residual Function and Insulin Needs in New-Onset Type 1 Diabetes

OBJECTIVE: This randomized, four-arm, placebo-controlled, dose-ranging phase 2 trial was conducted to determine whether repeated subcutaneous injections of the altered peptide ligand, NBI-6024, designed to inhibit autoreactive T-cells, improves β-cell function in patients with recently diagnosed typ...

Descripción completa

Detalles Bibliográficos
Autores principales: Walter, Markus, Philotheou, Areti, Bonnici, François, Ziegler, Anette-G., Jimenez, Roland
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768201/
https://www.ncbi.nlm.nih.gov/pubmed/19690081
http://dx.doi.org/10.2337/dc09-0449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768201/
https://www.ncbi.nlm.nih.gov/pubmed/19690081
http://dx.doi.org/10.2337/dc09-0449

Ejemplares similares